Sherryl J. Rosen, PMHCNS-BC Clinical Nurse Specialist - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 173 Oxford St, Lynn, MA 01901 Phone: 781-268-2200 Fax: 781-268-0465 |
Kate Vitt Fogarty, MSN Clinical Nurse Specialist - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 23 Central Ave, Lynn, MA 01901 Phone: 781-581-3900 |
Elizabeth Jo Jenkins Reimherr, RNCS Clinical Nurse Specialist - Psych/Mental Health, Child & Adolescent Medicare: Accepting Medicare Assignments Practice Location: 173 Oxford St, Lynn, MA 01901 Phone: 781-268-2200 Fax: 781-268-0465 |
Joan Longwell, RN MSNCS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Accepting Medicare Assignments Practice Location: 95 Pleasant St, Lynn, MA 01901 Phone: 781-581-4400 Fax: 781-592-0581 |
Nicole F Baisden, PMHCNS-BC Clinical Nurse Specialist - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 173 Oxford St, Lynn, MA 01901 Phone: 781-268-2200 Fax: 781-268-0465 |
Mrs. Julie Green Rowe, RN MS CS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Accepting Medicare Assignments Practice Location: 30 Boston St, Lynn, MA 01904 Phone: 781-592-6608 |
News Archive
More budget talks were expected Thursday as Minnesota's legislative session hurtled toward a midnight Sunday deadline with no deal on a $3 billion deficit. The Democratic-controlled Legislature defied another veto threat from Republican Gov. Tim Pawlenty late Wednesday and sent him a health and welfare package he opposes.
Researchers at the University of Minnesota's Lillehei Heart Institute have combined genetic repair with cellular reprogramming to generate stem cells capable of muscle regeneration in a mouse model for Duchenne Muscular Dystrophy (DMD).
Half the residents of New Orleans were suffering from poor mental and physical health more than a year after their homes and community were devastated by Hurricane Katrina in August 2005, according to research published in the September issue of the UK-based Journal of Clinical Nursing.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
Smokers trying to kick the habit might stand a better chance of staying smoke-free if they begin using replacement nicotine patches or gum in the weeks before they quit cigarettes.
› Verified 4 days ago